Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

• Status: Active, not recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To date one of the main independent biomarkers of cardiovascular disease is the arterial stiffness measured by carotid-femoral pulse wave velocity. It is known that SGLT2 inhibitors develop cardiac protection over long term administration.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centro Universitario de Ciencias de la Salud, Mexico
• Treatments: Dapagliflozin; Empagliflozin

Criteria

Inclusion Criteria:

• Diagnosis of T2DM

• HbA1c > 7 y < 10

• BMI 25 - 34.9 kg/m2

• Signature of consent under information

Exclusion Criteria:

• Hypertension

• Treated with insulin and / or loop diuretics and thiazides

• T1DM

• Hypotension

• Any autoimmune disease

• Liver disease

• Women whitout birth control method

• Women taking oral birth control or under hormone replacement therapy

• Woman pregnant or breastfeeding

• Untreated thyroid disease

• Patients with a cardiovascular disease that contraindicates the use of this pharmacological class

• Glomerular filtration rate <60ml/min (Cockcroft-Gault)